Klinikum Bremen-Ost

First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG (2025) Reinhard S, Utikal JS, Zaremba A, Lodde G, von Wasielewski I, Klespe KC, Meier F, et al. Journal article Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective (2024) Kähler KC, Gutzmer R, Angela Y, Livingstone E, Lodde G, Meiss F, Rafei-Shamsabadi DA, et al. Journal article The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects (2024) Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon Mv, Subklewe M, et al. Journal article Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity (2024) Wang Y, Ertl C, Schmitt C, Hammann L, Kramer R, Grabmaier U, Schöberl F, et al. Journal article S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma“ – update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention (2023) Leiter U, Heppt M, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, et al. Journal article S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care (2023) Heppt M, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, et al. Journal article S3-Leitlinie “Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Update 2023, Teil 1: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen (2023) Heppt M, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, et al. Journal article Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial) (2023) Kähler KC, Hüning S, Nashan D, Meiss F, Rafei-Shamsabadi DA, Rissmann H, Colapietro C, et al. Journal article COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma (2023) Berking C, Livingstone E, Debus D, Loquai C, Weichenthal M, Leiter U, Kiecker F, et al. Journal article Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study (2022) Berking C, Livingstone E, Weichenthal M, Leiter-Stoeppke U, Remy J, Eigentler T, Mohr P, et al. Conference contribution